This clinical trial is focused on studying the treatment of eosinophilic esophagitis, a condition where the esophagus becomes inflamed due to a high number of eosinophils, which are a type of white blood cell. The study is testing the effectiveness and tolerability of budesonide orodispersible tablets, which are designed to dissolve in the mouth. The trial compares two dosing schedules: taking 2 mg once daily versus 1 mg twice daily. The goal is to determine if the once-daily dose is as effective as the twice-daily dose in achieving histological remission, which means reducing the inflammation in the esophagus to a level that is not detectable under a microscope.

Participants in the study will be randomly assigned to one of the two dosing schedules. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which dosing schedule each participant is following. This helps ensure that the results are not biased. The trial will last for a period of six weeks, during which the participants will take the medication and undergo various assessments to monitor their condition and any changes in symptoms.

The primary focus of the study is to see how many participants achieve histological remission. Secondary aspects being observed include changes in the severity of symptoms such as difficulty swallowing (dysphagia) and pain when swallowing (odynophagia), as well as overall symptom severity. The study aims to provide valuable information on the best dosing schedule for treating eosinophilic esophagitis with budesonide orodispersible tablets.